Your Health. Your Family. Your Choice.
Life Threatening? No
Write-up: Death; This is a spontaneous report from a contactable physician via Regulatory Authority, downloaded from the Agency Regulatory Authority-WEB (NL-LRB-00462109). A 91-year-old male patient received the second dose of BNT162B2 (COMIRNATY; Lot number EP9598) via an unspecified route of administration on 02Mar2021 at single dose for COVID-19 immunisation. Relevant medical history included ongoing chronic kidney disease, ongoing vascular dementia and ongoing anaemia. Concomitant medications included acetylsalicylic acid (ACETYLSALICYLZUUR) 80 mg, metformin (METFORMINE) 250 mg, omeprazole (OMEPRAZOL) 20 mg, lorazepam 1 mg and tolterodine 2 mg. The patient previously took the first dose of BNT162B2 (COMIRNATY) for COVID-19 immunization on an unspecified date and risperidone on an unspecified date and experienced malaise, fluid intake reduced and consciousness decreased. The patient died on 02Mar2021, 3 hours after vaccination. The patient underwent lab tests and procedures on an unspecified date which included glomerular filtration rate 22 and haemoglobin 6.8. The cause of death was unknown. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected.; Sender''s Comments: Linked Report(s) : NL-PFIZER INC-2021261550 same patient, same vaccine, different events after different doses; Reported Cause(s) of Death: Unknown cause of death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166